Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma

Схожие документы

• Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma
  по: Chen, L, et al.
  Опубликовано: (2014)
• MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63
  по: Gamble, Laura D., et al.
  Опубликовано: (2011)
• Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma
  по: Chen, Lindi, et al.
  Опубликовано: (2019)
• Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer
  по: Zanjirband, Maryam, et al.
  Опубликовано: (2016)
• The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma
  по: Lakoma, A, et al.
  Опубликовано: (2015)